Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN. et al, (2022), Future Oncol
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Bueno C. et al, (2022), Blood, 140, 38 - 44
In utero origin of myelofibrosis presenting in adult monozygotic twins.
Sousos N. et al, (2022), Nat Med, 28, 1207 - 1211
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J. et al, (2022), Blood, 139, 2931 - 2941
Exploratory Analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
Harrison C. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 27 - 28
Longitudinal and Individual Symptom Analyses of Momelotinib and Ruxolitinib-Treated Myelofibrosis Patients from SIMPLIFY-1
Mesa R. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 79 - 80
Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis-update of clinical and translational data from the ongoing MANIFEST trial
Curto-Garcia N. et al, (2022), BRITISH JOURNAL OF HAEMATOLOGY, 197, 75 - 76
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
Mead AJ. et al, (2022), Ther Adv Hematol, 13
Defining disease modification in myelofibrosis in the era of targeted therapy
Pemmaraju N. et al, (2022), Cancer
Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors.
Neo WH. et al, (2021), Nat Commun, 12
A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Rice S. et al, (2021), Nat Commun, 12
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Gill H. et al, (2021), BLOOD, 138
Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN
Rodriguez-Meira A. et al, (2021), BLOOD, 138
The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP. et al, (2021), Br J Haematol, 195, 338 - 351
CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
Palandri F. et al, (2021), HAEMATOLOGICA, 106, 5 - 6
THE BET INHIBITOR, CPI-0610, PROMOTES MYELOID DIFFERENTIATION IN MYELOFIBROSIS (MF) PATIENT BONE MARROW AND PERIPHERAL CD34+HEMATOPOIETIC STEM CELLS
Vannucchi A. et al, (2021), HAEMATOLOGICA, 106, 51 - 51
Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development.
Roy A. et al, (2021), Cell Rep, 36